Tirzepatide produced more average weight loss
In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide over 72 weeks among adults with obesity who did not have type 2 diabetes. This was a randomized direct comparison, which is more informative for that question than placing results from unrelated trials beside each other.[1]
The result answers a group-level efficacy question. It does not establish the best choice for every patient, the best subscription company or the right way to switch medicines. Those questions involve eligibility, tolerability, clinical history, product access and a sustainable care arrangement.
What the headline numbers mean
The open-label trial enrolled 751 participants. Average weight change was −20.2% with tirzepatide and −13.7% with semaglutide at 72 weeks. Waist circumference fell by 18.4 cm and 13.0 cm respectively. Gastrointestinal adverse events were common in both groups, mostly mild or moderate and occurring during escalation. Eli Lilly funded the trial.[1]
| Reading the evidence | What it tells us |
|---|---|
| Randomized | Assignment helps make the groups comparable. |
| Open-label | Participants and clinicians knew the assigned treatment. |
| No type 2 diabetes | Do not automatically transfer the percentages to a diabetes population. |
| 72-week averages | Not an individual forecast or an early-treatment target. |
Subtracting the average weight changes gives a 6.5-percentage-point difference. That is not the same as saying every participant lost an additional 6.5% or that the difference appeared immediately. The timeline belongs beside the number.
Why cross-trial comparisons can mislead
Two studies can differ in who enrolled, how long treatment lasted, how missing measurements were handled and what support was offered. A direct trial reduces some of those problems by comparing treatments within one protocol. It does not remove all uncertainty or make every real-world treatment pathway identical to the study.
In particular, the study evaluated specified manufactured medicines and trial regimens. It did not establish equivalence for a compounded product, a different formulation or a marketplace bundle. A provider’s use of the same ingredient name is not sufficient to claim that its customers can expect the published averages.
The most effective plan must also be usable
A promising average matters less if the exact product cannot be obtained consistently or the care arrangement becomes unaffordable. That is a practical access issue, not a reason to dismiss efficacy evidence. Compare the medicine decision and the service decision in separate steps so one does not obscure the other.
Our semaglutide withdrawal article and tirzepatide maintenance article address different questions about what follows active treatment. They help explain why a short introductory price should not be the only time horizon in a comparison.
Use the trial to improve the comparison
The Ro review discusses access and membership costs, while the QuickMD review examines visit-based care with separate pharmacy spending. Neither review ranks clinical efficacy by the platform’s brand. The provider guides compare documented service features.
Use the appointment question builder to record what the clinician needs to explain about product choice, prior treatment and follow-up. If switching is being considered, the prescriber should determine the transition; a trial comparison is not a conversion chart.
The clearest reading is also the most useful: tirzepatide outperformed semaglutide on average weight loss in this defined trial. Keep that result intact, while leaving the individual treatment choice and the practical access plan to a separate, informed conversation.
The trial is not a provider ranking
The same clinical evidence can be relevant to people receiving care through different services. A platform does not acquire a superior expected treatment effect merely by placing the larger trial percentage beside its enrollment button. The study compares medicines under a protocol, not the quality of particular telehealth companies.
This distinction makes a shortlist easier to use. First discuss the appropriate product and treatment goals with a clinician. Then compare which service can support that plan with a clear cost, adequate follow-up and reliable coordination. If two quotes concern different products, do not force them into a single cheapest-provider table without labeling the difference. Efficacy, product status and service value are related decisions, but they are not the same measurement.
A treatment comparison should also name the outcome being prioritized. The largest average weight change is one outcome; tolerability, a specific approved indication and the ability to continue care may affect the individual decision differently.